ARTICLE | Company News

Genentech gets rights to Hanmi's pan-RAF inhibitor

September 29, 2016 7:00 AM UTC

Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940) granted the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) exclusive, worldwide rights, excluding South Korea, to develop and commercialize oncology candidate HM95573, a pan-RAF inhibitor that is in Phase I testing.

Hamni will receive $80 million up front and is eligible for up to $830 million in milestones, plus double-digit royalties. ...